PR88112

LUGANO, Switzerland, Feb. 21, 2021 /PRNewswire=KYODO JBN/ --

Timely presentations of trial data will accelerate transition from research to

practice

ESMO, the leading organisation for medical oncology, launches an important new

service for rapidly disseminating research to accelerate the transition of

results into practice for the benefit of cancer patients.

“In a world that runs fast, timeliness in bringing research advances to

patients is critical. The lessons that we have learnt from the COVID-19

pandemic have taught us that we need to be creative in sharing research

results, and we certainly don’t have to wait for the two or three times in the

year when major oncology congresses take place,” says Solange Peters, ESMO

President [https://www.youtube.com/watch?v=dki6f-icm8g&feature=youtu.be].

ESMO Virtual Plenaries will combine concise presentations of new data,

insightful discussion and audience Q&A in live, easy-to-access, 60-minute

online sessions at convenient times across time zones. They will remain

available on OncologyPRO, ESMO’s online resource portal, for subsequent viewing.

Every month, latest, original scientific data will be presented from randomised

phase III oncology trials or phase II trials which demonstrate remarkable

therapeutic benefit, scientific insight or progress in an area of unmet need.

“By timely presentation of clinical and scientific data, ESMO Virtual Plenaries

will be complementary to and enhance the value of conventional scientific

congresses, whilst adhering to the principles of peer review, analysis and

audience interaction,” says George Pentheroudakis, ESMO CMO.

Two abstracts maximum will be accepted for presentation each month (except

September and November when ESMO hosts major congresses). Abstracts will be

original data from international investigators, selected by appropriate

independent ESMO specialists. After presentation in ESMO Virtual Plenaries,

abstracts will be published in Annals of Oncology and will be eligible for

encore presentation at the next ESMO Congress.

The first ESMO Virtual Plenary is Friday, 19 February, 1300 CET

Efficacy of everolimus in patients with HR+/HER2- high risk early-stage breast

cancer

（https://www.esmo.org/meetings/esmo-virtual-plenaries/efficacy-of-everolimus-in-patients-with-hr-her2-high-risk-early-stage-breast-cancer ）

The ESMO Virtual Plenaries

[https://www.esmo.org/meetings/esmo-virtual-plenaries] are freely available to

all healthcare professionals working in Oncology. Anyone with an already

existing free ESMO Account

[https://esmo.force.com/esmo/s/registeruser?startURL=https%3A%2F%2Fesmo.org%2F]

will be able to access and watch.

Photo - https://mma.prnewswire.com/media/1439138/ESMO_Virtual_Plenaries.jpg

ESMO Press Office

+41919731901

media@esmo.org

Source: European Society for Medical Oncology (ESMO)